Findings from more than 2,000 respondents in 16 countries underscore the debilitating and under-reported effects of sickle cell disease and a pattern of not seeking care despite potentially life-threatening symptoms1 Patients reported on average more t…
Once-daily QMF149 met primary endpoint of lung function improvement and key secondary endpoint of asthma control improvement versus mometasone furoate1 QMF149 showed improvement in peak expiratory flow, exacerbation rates, rescue medication use versus …
Our drug discovery and development engine has the scope and scale to innovate the next generation of medicines. We’re harnessing powerful and advanced therapy platforms to take on big scientific challenges and find opportunities to develop breakthrough…
Uniquely positioned with global scale, focus on innovative medicines, diversification across therapeutic areas and exposure to cutting-edge platforms60 projects in Phase 2 pipeline with 10+ advancing into Phase 3 or pivotal trials each year in 2020 and…
Basel, December 5, 2019 — Novartis AG (NYSE: NVS) (“Novartis”) today announced that its indirect wholly-owned subsidiary, Medusa Merger Corporation, a Delaware corporation (“Purchaser”), has commenced a cash tender offer to purchase all of the outstand…
On Wednesday December 4, 2019 Amazon Web Services announced a strategic collaboration with Novartis that will leverage AWS’s broadest portfolio of cloud services to build an enterprise-wide data and analytics platform that will transform business opera…
On Wednesday December 4, 2019 Amazon Web Services announced a strategic collaboration with Novartis that will leverage AWS’s broadest portfolio of cloud services to build an enterprise-wide data and analytics platform that will transform business opera…
At the American Society of Hematology (ASH) Annual Meeting & Exposition and the San Antonio Breast Cancer Symposium (SABCS) in December, Novartis will present more than 180 abstracts. We have a rich history of research and development (R&D) in …
With more than 140 abstracts, Novartis continues its leadership in hematology innovation Data for MBG453, an innovative anti-TIM-3 immunotherapy, with decitabine on preliminary response rates in patients with high-risk MDS and AML Safety and efficacy …
In the presence of Federal Councillor Alain Berset and other distinguished guests, Novartis inaugurated a new manufacturing facility for cell and gene therapies at Stein, Switzerland on November 28th.“Our site in Stein is vital for new launches of soli…